Hepatitis B Virus Core Antigen (HBcAg) 抗体 (Alexa Fluor 555)
-
- 抗原 See all Hepatitis B Virus Core Antigen (HBcAg) 抗体
- Hepatitis B Virus Core Antigen (HBcAg)
-
适用
- Hepatitis B Virus (HBV), Virus
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- Alexa Fluor 555
-
应用范围
- Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- 交叉反应
- Virus
- 交叉反应 （详细）
- Hepatitis B Virus
- 纯化方法
- Purified by Protein G.
- 免疫原
- Recombinant Hepatitis B Core Antigen (rHBcAg)
- 克隆位点
- 1H8
- 亚型
- IgG
- Top Product
- Discover our top product HBcAg Primary Antibody
-
anti-Hepatitis B Virus Core Antigen (HBcAg) antibody
HBcAg 适用: Hepatitis B Virus (HBV), Virus ELISA, IHC (p), IF (p) 宿主: 小鼠 Monoclonal 1H8 unconjugated
-
- 应用备注
- IF(IHC-P) 1:50-200
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 μg/μL
- 缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 有效期
- 12 months
-
- 抗原
- Hepatitis B Virus Core Antigen (HBcAg)
- 别名
- HBcAg (HBcAg 产品)
- 别名
- precore; HBe antigen; PreC; HBeAg; precore protein; external core antigen; HBeAg; p25 antibody, C antibody
- 物质类
- Viral Protein
- 背景
-
Synonyms: C, Capsid protein, Core and e antigen, Core antigen, Core antigen, Core protein, HBc, HBcAg, HBVgp4, Hepatitis B Virus core antigen, p21.5, precore/core protein, CAPSD_HBVA3.
Background: Hepatitis B Virus Core Antigen (HBcAg) is part of the infectious virion containing an inner "core particle" enclosing the viral genome. The icosahedral core particle contains 180 or 240 copies of the core protein. HBcAg is one of the three major clinical antigens of hepatitis B virus but disappears early in the course of infection.The hepatitis B virus core antigen (HBcAg) is a highly immunogenic subviral particle and functions as both a T-cell-dependent and a T-cell-independent antigen. Therefore, HBcAg may be a promising candidate target for therapeutic vaccine control of chronic HBV infection.
-
